I-Mab (NASDAQ:IMAB) went up by 0.89% from its latest closing price compared to the recent 1-year high of $85.40. The company’s stock price has collected -3.95% of loss in the last five trading sessions. Press Release reported on 11/10/21 that I-Mab and Jumpcan Announce Strategic Commercial Partnership on Eftansomatropin Alfa
Is It Worth Investing in I-Mab (NASDAQ :IMAB) Right Now?
Opinions of the stock are interesting as 13 analysts out of 14 who provided ratings for I-Mab declared the stock was a “buy,” while 1 rated the stock as “overweight,” 0 rated it as “hold,” and 0 as “sell.”
The average price from analysts is $95.44, which is $31.02 above the current price. IMAB currently public float of 30.44M and currently shorts hold a 8.18% ratio of that float. Today, the average trading volume of IMAB was 522.70K shares.
IMAB’s Market Performance
IMAB stocks went down by -3.95% for the week, with a monthly jump of 2.22% and a quarterly performance of 3.16%, while its annual performance rate touched 74.68%. The volatility ratio for the week stands at 4.54% while the volatility levels for the past 30 days are set at 5.10% for I-Mab. The simple moving average for the period of the last 20 days is 3.01% for IMAB stocks with a simple moving average of -1.45% for the last 200 days.
Analysts’ Opinion of IMAB
Needham, on the other hand, stated in their research note that they expect to see IMAB reach a price target of $75. The rating they have provided for IMAB stocks is “Buy” according to the report published on March 15th, 2021.
H.C. Wainwright gave a rating of “Buy” to IMAB, setting the target price at $75 in the report published on March 03rd of the current year.
IMAB Trading at -3.06% from the 50-Day Moving Average
After a stumble in the market that brought IMAB to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -23.99% of loss for the given period.
Volatility was left at 5.10%, however, over the last 30 days, the volatility rate increased by 4.54%, as shares surge +4.78% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -4.71% lower at present.
During the last 5 trading sessions, IMAB fell by -3.95%, which changed the moving average for the period of 200-days by +12.55% in comparison to the 20-day moving average, which settled at $63.16. In addition, I-Mab saw 37.67% in overturn over a single year, with a tendency to cut further gains.
Stock Fundamentals for IMAB
Current profitability levels for the company are sitting at:
- +10.08 for the present operating margin
The net margin for I-Mab stands at +30.53. The total capital return value is set at 4.36, while invested capital returns managed to touch 13.30. Equity return is now at value -0.50, with -0.50 for asset returns.
Based on I-Mab (IMAB), the company’s capital structure generated 0.24 points at debt to equity in total, while total debt to capital is 0.24. Total debt to assets is 0.21, with long-term debt to equity ratio resting at 0.10. Finally, the long-term debt to capital ratio is 0.10.
When we switch over and look at the enterprise to sales, we see a ratio of 18.89, with the company’s debt to enterprise value settled at 0.00. The receivables turnover for the company is 5.64 and the total asset turnover is 0.37. The liquidity ratio also appears to be rather interesting for investors as it stands at 9.28.